Bedrock Affect Client: Phenomic AI

Phenomic.AI is developing a platform that uses deep learning to systematically target chemotherapy resistance – an event which underpins 90% of all cancer treatment failures and accounts for millions of annual deaths worldwide. The deep learning models being created by the company today will eventually be used to develop novel biomarkers and therapeutics to fight against cancer.

The platform Phenomic is developing will enable the prediction of chemotherapy resistance at the single cell level. This will enable live cell microscopy analysis that will predict which cells will be affected by chemotherapy treatments. Ultimately, these models will enable the discovery of novel biomarkers and therapeutics which Phenomic will develop and bring to market.



CO-FOUNDERS: Sam Cooper (CEO), Oren Kraus (CSO)

Bedrock Affect: